Press release
OPCA Celebrates Passage of HB 2385 to Protect Access to Lifesaving Medications for Oregonians
June 12, 2025, Portland, OR -The Oregon Primary Care Association (OPCA) commends the state legislature and Governor Tina Kotek for passing House Bill 2385. This new law protects Oregonians' access to comprehensive primary, behavioral, and oral health care services at Oregon's federally qualified community health centers (FQHCs). It also ensures that patients can access affordable, life-saving medications under the federal 340B drug pricing program.The 340B program requires drug manufacturers to give discounts on the medications they sell to eligible safety net providers like FQHCs and hospitals. These eligible medical providers accept all patients, regardless of their ability to pay. The 340B discounts are essential to ensure patients' access to affordable medications. Moreover, safety net clinics reinvest their cost savings under 340B into services like behavioral health, dental care, and mobile clinics which further advance population health.
Since 2020, Oregonians' access to 340B discounts has been under threat from drug manufacturers who refused to provide discounts to community health centers working with local pharmacies. Drug manufacturers' restrictions force patients to travel farther to fill prescriptions and prevent safety net providers from accessing 340B savings. OPCA surveyed members and determined that the restrictions cost Oregon FQHCs an estimated $10 million in lost savings in 2024.
"That's $10 million that should have stayed in Oregon communities and instead went into manufacturer shareholders' pockets," said Marty Carty, OPCA's Director of Government Affairs.
HB 2385 forbids pharmaceutical manufacturers from restricting where these medications can be dispensed. The bill is informed by similar laws enacted in 15 states across the country (UT, NM, NE, SD, ND, MN, MO, AR, LA, MS, TN, WV, MD, CO, HI). HB 2385 also includes an essential enforcement provision which empowers the Oregon Board of Pharmacy to impose fines on non-compliant manufacturers.
"This is a vital victory for community health," said Carty. "When drug manufacturers arbitrarily limit the number of pharmacies eligible to dispense 340B medications, it becomes harder for patients, especially in rural areas, to access the prescriptions they need. HB 2385 puts those decisions back in the hands of local providers."
OPCA thanks Representative Rob Nosse, Senator Deb Patterson, and all the members of Oregon's Legislature who voted to strengthen and protect the state's health care safety net. With this law in place, Oregon joins a growing coalition of states defending the integrity of the 340B program.
Media Contact:
Marty Carty
Director of Government Affairs
Oregon Primary Care Association
Email: mcarty@orpca.org
Phone: 503-930-6812
Address: 623 SW Oak St., Suite 300, Portland, Oregon 97205
The Oregon Primary Care Association (OPCA) is the voice of Oregon's Federally Qualified Health Centers (FQHCs), which deliver integrated medical, dental, and behavioral health services to more than 471,000 Oregonians at over 270 locations statewide.
OPCA fosters collaboration through training, technical assistance, and operational support. Additionally, OPCA collects and analyzes statewide data to inform policy and regulatory improvements that reduce barriers to care and strengthen the state's community health centers.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release OPCA Celebrates Passage of HB 2385 to Protect Access to Lifesaving Medications for Oregonians here
News-ID: 4064744 • Views: …
More Releases for OPCA
Olivopontocerebellar Atrophy Market Size, Share & Trends [2025-2034]
The Olivopontocerebellar Atrophy Market Is Set To Grow At An Estimated CAGR Of 8.3% From 2025 To 2034, Rising From $1.3 Billion In 2024 To $2.8 Billion By 2034.
On April 16, 2025, Exactitude Consultancy., Ltd. released a research report offers a comprehensive examination of the various processes and materials used in the production of Olivopontocerebellar Atrophy market goods. The market study excludes key regions that are accelerating marketization. This section…
Wholesale Telecom Carrier Market Expands with Increased Data Consumption
Global Wholesale Telecom Carrier Market, By Solutions (Voice Termination, SMS Messaging Services, VoIP Solutions, Data Roaming Services, International Call Services, SIP Trunking, Mobile Number Portability, Cloud Communication Services, Network Security Solutions,), Organization Size (SMEs and Large Enterprises), End-User (Internet Service Providers (ISPS), Mobile Network Operators (MNOS), VoIP Service Providers, Cable TV Operators, Government Agencies, Educational Institutes, Content Providers, and Other) - Industry Trends and Forecast to 2031.
Data Bridge Market Research…
Multiple System Atrophy Pipeline | Clinical Trials and Key Companies
DelveInsight's, "Multiple System Atrophy - Pipeline Insight, 2023," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Multiple System Atrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download Sample Report to know more @ https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Multiple…
Multiple System Atrophy Market Size was approximately USD 125 million in 2022
"With the expected launch of emerging therapies, the multiple system atrophy market is expected to show positive growth in the forecast period in the 7MM. Moreover, increased awareness of MSA has amplified drug research and development"
The Multiple System Atrophy market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Multiple System Atrophy market size from 2019 to 2032. The report also covers…
Olivopontocerebellar Atrophy Market Industry Analysis and Forecast Till 2027|Pfi …
Olivopontocerebellar Atrophy (OPCA) is a rare neurodegenerative disorder described by Olivopontocerebellar Atrophy (OPCA). Disequilibrium, disability or inability to coordinate voluntary movements (cerebellar ataxia), and difficulty in speech (dyarthia) are all symptoms of these diseases. Clinical, genetic, and neuropathological factors have been used to classify OPCA. OPCA can be passed down the generations or acquired. The global Olivopontocerebellar Atrophy market size is projected to reach US$ XX million by 2027, from…